For Black Diamond Therapeutics Inc. (BDTX), this quarter is shaping up to be an eventful period, with multiple clinical trial catalysts anticipated across its MasterKey portfolio.
The company's Masterkey therapy approach targets families of oncogenic mutations, enabling an expanded addressable patient population. Designed to be potent across broad mutation families, including drug-resistant variants, with brain-penetrant properties to treat CNS disease, while maintaining selectivity for better tolerability. In contrast, the traditional oncology approach focuses on targeting single mutations within specific tumor types, often limiting patient reach and making it more vulnerable to resistance.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.